--- title: "Bio-Rad Laboratories (NYSE:BIO.B) Shares Pass Below 200-Day Moving Average - Time to Sell?" type: "News" locale: "en" url: "https://longbridge.com/en/news/276510176.md" description: "Bio-Rad Laboratories (NYSE:BIO.B) shares have fallen below their 200-day moving average of $289.87, trading at $261.83. The company reported a P/E ratio of 9.38, a market cap of $7.06 billion, and a net margin of 29.42%. Analysts currently hold a 'Hold' rating on the stock, suggesting it may not be a favorable buy compared to other recommended stocks. The firm operates in life sciences and clinical diagnostics, providing innovative products and systems for research and testing." datetime: "2026-02-21T10:18:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276510176.md) - [en](https://longbridge.com/en/news/276510176.md) - [zh-HK](https://longbridge.com/zh-HK/news/276510176.md) --- # Bio-Rad Laboratories (NYSE:BIO.B) Shares Pass Below 200-Day Moving Average - Time to Sell? Bio-Rad Laboratories, Inc. (NYSE:BIO.B - Get Free Report) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $289.87 and traded as low as $261.83. Bio-Rad Laboratories shares last traded at $261.83, with a volume of 100 shares traded. Get **Bio-Rad Laboratories** alerts: ## Bio-Rad Laboratories Price Performance The firm has a 50 day moving average of $302.18 and a 200-day moving average of $289.87. The company has a current ratio of 5.62, a quick ratio of 4.19 and a debt-to-equity ratio of 0.16. The company has a market cap of $7.06 billion, a P/E ratio of 9.38 and a beta of 1.01. Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The company reported $2.51 earnings per share (EPS) for the quarter. Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. The business had revenue of $693.20 million during the quarter. ## Bio-Rad Laboratories Company Profile (Get Free Report) Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad's product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR. In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows. ## Further Reading - Five stocks we like better than Bio-Rad Laboratories - The gold chart Wall Street is terrified of… - Buy this Gold Stock Before May 2026 - What a Former CIA Agent Knows About the Coming Collapse - This $15 Stock Could Go Down as the #1 Stock of 2026 - New gold price target _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Bio-Rad Laboratories Right Now? Before you consider Bio-Rad Laboratories, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list. While Bio-Rad Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [BIO.B.US](https://longbridge.com/en/quote/BIO.B.US.md) - [BIO.US](https://longbridge.com/en/quote/BIO.US.md) ## Related News & Research - [Assessing Bio-Rad (BIO) Valuation After Recent Share Price Weakness And Longer-Term Return Pressures](https://longbridge.com/en/news/275997412.md) - [Bio-Rad Q4 revenue slightly beats estimates, helped by growth in Clinical Diagnostics unit](https://longbridge.com/en/news/275809784.md) - [Aqua Bio Technology Registers Share Capital Increase After Subsequent Offering](https://longbridge.com/en/news/282325318.md) - [CAI Marks Thirty Years Advancing Operational Readiness and Excellence Across Life Sciences and Mission-Critical Industries](https://longbridge.com/en/news/282541838.md) - [ZAWYA: CE-Ventures announces acquisition of portfolio company CrossBridge Bio by Eli Lilly](https://longbridge.com/en/news/282695762.md)